2020年度6月定例理事会・委員会会議

2020年度6月定例理事会・委員会会議が開催されました

直近ですと通常京都で開催されていました6月定例理事会・委員会会議がオンラインで開催されました。コロナ禍が始まった昨年度は、予定していた学術集会が急遽取りやめとなり、理事・委員会の先生方も対応に追われていたことと思います。今年は無事オンラインで開催されました。

議題は予め回覧されていました委員会の活動報告・各種情報共有・審議事項の審議でした。必要な情報は追って会員に展開されることでしょう。

JPCERT/CCからJVNとしてWordPressに脆弱性があると報告がありました

本ホームページは、東京大学医学部附属病院に物理的なサーバーがありまして、大学病院医療情報ネットワーク(UMIN)が提供するサービスを利用しています。そのUMINの担当者よりホームページ管理者まで、タイトルの様なセキュリティ上のお知らせが時折入ります。(下表)

本ホームページでは、タイトルにありますWordPressというホームページのコンテンツを管理するシステムを使用しております。ですので、タイトルの様なお知らせが入りましたら、できるだけ速やかにデータベースをバックアップして、最新のバージョンにアップデートします。私自身、そんなに慣れていないこともあって、この作業には1回で数時間を要します。今回は金曜日にお知らせを受信いたしまして、日曜日の午後にその作業を行いました。

(PRC委員長 大島康雄)

表)直近のお知らせの日付とタイトル

日付     タイトル
2019/06/19 WordPressの脆弱性に関する注意喚起
2019/05/30 WordPressの脆弱性に関する注意喚起
2019/03/20 WordPressプラグインに複数の脆弱性
2019/03/06 WordPressプラグインに複数の脆弱性
2019/01/17 WordPressプラグインに複数の脆弱性
2019/01/09 WordPressプラグインに複数の脆弱性
2018/12/20 WordPressに複数の脆弱性
2018/11/14 WordPressプラグインに複数の脆弱性
2018/11/07 WordPressプラグインに複数の脆弱性
2018/07/25 WordPressプラグインに複数の脆弱性
2018/07/11 WordPressプラグインに複数の脆弱性
2018/06/06 WordPressプラグインに複数の脆弱性
2018/05/16 WordPressプラグインに複数の脆弱性
2018/03/14 WordPressプラグインに複数の脆弱性
2018/02/07 WordPressプラグインの脆弱性に関する注意喚起
2017/11/22 WordPressプラグインの脆弱性に関する注意喚起
2017/08/30 WordPressプラグインの脆弱性に関する注意喚起
2017/08/03 WordPressプラグインの脆弱性に関する注意喚起
2017/07/12 WordPressプラグインの脆弱性に関する注意喚起
2017/06/21 WordPressおよびプラグインに複数の脆弱性
2017/06/14 WordPressおよびプラグインに複数の脆弱性
2017/06/06 WordPressおよびプラグインに複数の脆弱性
2017/05/24 WordPressおよび、プラグインの脆弱性に関する注意喚起
2017/04/26 WordPress用プラグインBooking Calendarの脆弱性に関する注意喚起
2017/03/15 WordPressおよびOneThird CMSに脆弱性
2017/02/09 WordPressの脆弱性に関する注意喚起

New Member of Public Relations Committee

Committee: Public Relations Committee

Job Title: Associate Professor

Name: Hiroo Wada

Degree: MD, MBA, PhD, FACP

Institution: Juntendo University

Division/Department: Public Health

Hobby: Tennis, Travel

Message: I believe ACP activities will provide us, physicians, with the applicable knowledge & skills in the fields of clinical medicine and public health.

New Member of Student Committee

Committee: Student Committee

Job TitleStudent

Name: Keiko Tsukamoto

Institution: School of Medicine

Division/Department: Tokai University

Hobby: Swimming, Cello, Traveling

Message: Carpe diem

Governor’s Message

 

Dear ACP members and friends,

I hope you and your families are safe and well.

As covid-19 spreads around the world including this country, I believe all of you, more or less, have involved in the fight against the virus. Thank you for everything for you’re doing on a daily basis to support one another and your patients.

Normally, in this timing of newsletter, I would tell about the success of the recent ACP meeting, the Internal Medicine Meeting 2020, but as you may have already known, it was unfortunately cancelled.

We too had to cancel all the schedule concerning our chapter meeting in June due to this crisis, although now it seems that the first wave of the awful pandemic is passing…

As for the information concerning the pandemic, ACP is compiling first-hand accounts and relevant resources from the internal medicine community during these challenging times, helping you stay informed with the latest articles. You can find the resources on the ACP website. “COVID-19: An ACP Physician’s Guide” is available at the top page. (If it’s not available, access the Clinical Information bar at the top.) It is a great resource provided by ACP!

I look forward to reuniting as a chapter. Until then, stay safe and well.

Sincerely,

Kenji Maeda, MD, FACP

ACP Japan ChapterホームページのPWA化

Progressive Web App (PWA)化とは

このホームページへアクセスする際に、ブラウザを起動して、ホームページのアドレスを入力するか、ブックマークを探してクリックするという方法で見ておられるかたもいらっしゃると思います。それをホーム画面のアイコンをクリックすることでアクセスできるようにすることです。

iOSでPWA化する際の手順です

1.当サイトへiPhone, iPod, iPadのいずれかからアクセスし、画面下の真ん中にあるアイコンをタップします。

私のiPadで試したところ、同様のメニューが右上に現れました。プラットフォームやOSの版によってメニューが表示される場所が異なるかもしれません。

2.下から出てくるメニューで、「ホーム画面に追加」をタップしましょう。

3.「ホーム画面に追加」画面になります。「アイコン」や「アイコンショート名」が正しく表示されているかを確認します。

4.「追加」できるとこんな感じでホーム画面にアイコンが並びます。

5.アプリアイコンをタップすると、こんな感じに全画面で表示されるはずです。(URLバーがない)

(PRC委員長 大島康雄 投稿)

医師のバーンアウトについてのアンケート(Mini-Z2.0日本語版)のご依頼

ACP日本支部Physicians’ Well-being Teamから医師のバーンアウトについてのアンケート(Mini-Z2.0日本語版)への参加のお願いです。
先生方の身の回りでも医師のバーンアウトは既に身近な問題かと思います。日本における医師のバーンアウトに関する研究や情報はまだ少なく、自分たちの現状を知り実効性のある対策を考える契機になる(長い目で見れば、自分たちの職場環境を見直す契機になる)かと存じますし、今回の結果をもとにこの問題に対して我々ACP日本支部が社会に対して声を上げていくことは日本支部としての重要な使命の一つだと思います。また、ACP日本支部MLを通じてアンケート調査を行い種々の問題に関する支部会員の現状を把握するというプラクティスは今後重要なツールになってくるかとも存じます。ぜひご協力をお願い致します。
アンケートはこちらです↓
対象はACP日本支部会員医師学生会員の方は今回は対象となりません。また会員以外の方も今回は対象とはなりませんので悪しからずお聞き流し下さい)で、締め切りは1月末を予定しています。お忙しいところ恐縮ですが、それほどお時間はかかりません(3−5分ほど)。どうぞ宜しくお願い致します。
なお、アンケートの集計結果については、本年6月のACP日本支部総会でのWomen’s committeeと日本支部Physicians’ Well-being Team共催のセッション(予定)等にて共有させて頂きます。
ACP日本支部Physicians’ Well-being Team

Governor’s Message

Dear Fellow ACP Japan Chapter Members,

I hope each of you is enjoying a busy but wonderful season.
As the first year of my term as Governor of Japan Chapter, I’d like to express my appreciation for your support. And thanks to the members who helped us spending time and energy, especially lots of thanks to various committee members.

Now we are going internationally. The first Asian Regional Chapters Conference will take place in Kochi in India in August 2020. It was accomplished through endeavors of Governors from India, Bangladesh and South-East Asian Chapters.
The guest speakers from India and Bangladesh will participate in our Chapter meeting in Kyoto in June 2020. There will also be a guest from ACP headquarter in the USA, and we’ll have the first “Thieves’ Market” session in Japan, one of popular sessions in the Internal Medicine Meetings in the USA, which will be presented by Dr. David Scrase.

At the national level, we began to cooperate with both of Japan Primary Care Association and Society for Clinical Epidemiology. Its activity is called as “Primary Care Research Connect” or “PCR Connect”. The first conference of PCR Connect will take place soon in early this month, December 8th. Also we keep cooperating with the Japanese Society of Internal Medicine (JSIM), we are planning to hold a 2nd session with them in the coming JSIM annual meeting in Tokyo in April 2020.

Various committees in our Chapter are acting vigorously. For example, Resident Fellow Committee (RFC) is giving two clinical seminars a year for residents, and International Exchange Program Committee (IEPC) is trying to send young physicians out to oversea medical institutions for short-term study by observation. Other committees are working hard as well. The Japan Chapter is steadily progressing.

The best of the holiday season to you all and your families.

Kenji Maeda, Governor of Japan Chapter

複合語候補ITC103

複合語スコア
heart failure11362.654529566
chronic heart failure519.90606666886
symptoms of heart failure513.21411655139
n engl j med390.00549803189
heart failure hospitalization356.42102496814
congestive heart failure280.57032391471
coronary artery disease277.15825556087
j am coll cardiol271.7851694969
iv heart failure224.04269055375
systolic heart failure187.10772077547
heart rate177.54273087838
severe heart failure171.42592868794
decompensated heart failure164.42484855543
ejection fraction164.27110467461
incident heart failure163.40050263775
et al153.3196976963
management of heart failure147.17527658401
diastolic heart failure147.17527658401
american heart association143.75766327291
acute decompensated heart failure143.51945164387
new-onset heart failure141.21630632987
heart failure society of america120.506594213
incidence of heart failure118.88245834328
heart disease115.51473789864
ace inhibitors104.12993381006
myocardial infarction97.141201813281
symptomatic heart failure95.180225031078
ventricular dysfunction91.927834917645
nyha class ii89.843380196645
advanced heart failure77.875396291055
diagnosis of heart failure76.36157006205
heart failure trial74.680896851249
valsartan heart failure trial69.316207802652
suspected heart failure68.030424883464
clinical heart failure67.671396040077
structural heart disease65.794994603193
development of heart failure64.845532444825
heart work61.502606079176
risk factors56.78140354932
increased risk55.130657644958
systolic dysfunction53.149688412681
treatment of heart failure52.64902149553
heart failure patients52.488256746022
history of heart failure49.058425528003
heart failure outcomes48.828628936152
prevention of heart failure48.828628936152
common cause of heart failure46.217324350561
diastolic dysfunction44.493513012808
accf/aha stages of heart failure43.933256091005
acute heart failure43.291703567625
ventricular hypertrophy42.556750670457
blood pressure40.912311036161
ace inhibitor40.465445621929
acute myocardial infarction39.157846511086
valvular heart disease39.07778423469
progression of heart failure38.937698145528
reduced ejection fraction38.279943609919
cardiac transplant38.088840897721
nyha class37.168436488375
systolic heart failure treatment36.624624147531
clinical trial36.514252915594
type of heart failure36.393324585865
end-stage heart failure36.393324585865
new heart failure36.393324585865
chronic systolic heart failure36.280570898978
heart failure hospitalizations35.304076582467
heart failure information35.304076582467
new york heart association35.161605961199
chronic heart failure therapy34.119607961832
heart failure exacerbations34.015212441732
mild heart failure34.015212441732
heart outcomes prevention evaluation32.550361330155
overt heart failure32.422766222413
refractory heart failure32.422766222413
standard medical therapy32.220500574413
comprehensive heart failure practice guideline30.512498229377
established heart failure30.30410916161
undiagnosed heart failure30.30410916161
preserved ejection fraction29.847191914672
primary symptoms of heart failure29.832302124903
current symptoms of heart failure29.396302199663
severe symptoms29.302732011878
chronic congestive heart failure29.232377228144
ventricular ejection fraction29.073272214158
nyha class ii heart failure28.730557789481
severe decompensated heart failure28.487192131714
butler j27.817093114978
functional cause of heart failure symptoms27.674153402284
high risk27.565328822479
severe chronic heart failure27.381589902864
coronary disease27.162114335027
nonischemic systolic heart failure27.139328065196
functional class27.089969968019
severe symptomatic heart failure25.624331641334
advanced chronic heart failure25.481440613546
non-ischemic systolic heart failure25.460562669705
severe congestive heart failure25.289070095955
renal function25.135581073296
primary cause of heart failure24.870462797164
stage c heart failure24.649903576842
all-cause mortality24.578701598965
pitt b23.905695622382
valsartan heart failure trial investigators23.623333128789
nyha class iii23.577076175429
eur heart j23.377254482009
long-term management of heart failure23.190179526877
left ventricular systolic dysfunction22.710284630869
ventricular pacing22.70333804263
african american heart failure trial22.64064168927
standard therapy22.62189070204
left ventricular dysfunction22.095958211392
family history of heart failure22.044116795314
health burden of heart failure21.8669953659
pulmonary artery pressure21.802122352441
cardiovascular death21.65736770668
myocardial ischemia21.502111138339
randomized trial of patients21.281414946154
population burden of heart failure21.265488388788
high blood pressure20.387204864274
borderline diastolic heart failure20.214544230179
physical activity19.991995195515
yusuf s19.817003712138
different stages of heart failure19.759060825555
african-american heart failure trial investigators19.74813326343
early evidence of heart failure19.589389217353
advanced end-stage heart failure19.500538833241
clinical trials19.364606884933
cases of incident heart failure19.215537915851
modifiable risk factors19.096568395957
heart catheterization19.078208021575
cardiovascular disease18.95254888215
heart failure incidence increases18.782564580814
jacc heart fail18.673112610951
treatment of preserved cardiac function heart failure18.550149920084
palliative care18.44179994736
total cost of heart failure18.265902668449
nyha functional class iii heart failure patients18.217454040627
medical therapy17.964918147966
natural progression of heart failure17.882072954752
emergency diagnosis of heart failure17.620725961188
framingham heart study17.498080233577
other risk factors17.278687223499
heart murmur17.23910699358
heart pumps17.23910699358
randomized aldactone evaluation study17.087538022693
clinical manifestations16.83639757978
american college of cardiology/american heart association task force16.535658500992
sinus rhythm16.413388798409
rate control16.264836064977
isosorbide dinitrate15.731731418229
atrial fibrillation14.831171004269
effect of enalapril14.810436756732
reduced left ventricular ejection fractions14.67049846495
clinical practice guidelines14.331909251528
standard oral heart failure medications14.300957322253
ventricular systolic dysfunction14.250752107168
cardiac resynchronization-heart failure14.182398182435
b-type natriuretic peptide14.104527674707
seattle heart failure model14.084936415565
heart outcomes prevention evaluation study investigators13.643378821151
natriuretic peptide13.63463239761
myocardial dysfunction13.339979404194
large randomized controlled trial13.319992037631
significant difference13.239003678587
cardiac resynchronization13.127272139645
randomized trial12.804343491775
mcmurray jj12.728649475109
symptomatic patients12.688455161287
primary prevention12.638597791832
weight gain12.358602863443
pulmonary artery12.189889456761
high-risk patients12.160801393263
natriuretic peptide-guided therapy12.148130455988
presence of risk factors12.135032696779
mechanical circulatory support12.05693358307
nonischemic cardiomyopathy11.988264044641
svensson am11.741784511603
ventricular function11.641674912519
left ventricular ejection fraction11.525563868743
asymptomatic patients11.500975876433
functional capacity11.465313506452
nhlbi heart failure clinical research network11.358108274759
survival study11.233623397695
icd implantation11.19016562612
jessup m. stage b heart failure11.118430014839
eplerenone post-acute myocardial infarction heart failure efficacy10.997210408437
hospitalization rates10.954451150103
global myocardial ischemia10.912809166167
systolic blood pressure10.88520498932
ventricular volume10.702456190343
quality of life10.669676460234
physical examination10.602356529148
microvascular disease10.487221590056
right heart catheterization10.4799301148
specific causes10.392304845413
bozkurt b10.392304845413
trial investigators10.388739120117
reduced risk10.261558002989
controlled trial10.182919580087
nyha functional classification10.142555229712
clinical practice10.102415878263
pulmonary disease10.019940278469
cardiovascular mortality9.9312951847935
inotropic agents9.7291971163912
clinical outcomes9.6522804347375
moderate symptoms9.6411410273358
systolic blood pressure intervention trial9.6084651563334
aldosterone antagonist9.603257618831
study investigators9.5876942772625
current guidelines9.5803106027242
intravenous inotropic agents9.5374267604657
acute coronary syndrome9.4985091341904
american college of cardiology foundation9.3845904936053
controlled trial of patients9.1337089660923
american heart association statistics committee8.9787339517073
coronary revascularization8.9720926873273
cohn jn8.9442719099992
other causes8.9442719099992
induced coronary artery disease8.847853494422
specific cause8.8186670410496
disease control8.8186670410496
circ heart fail8.7264615096001
angiotensin receptor?neprilysin inhibitor8.7211839342619
survival study investigators8.6332728113428
wilson j8.6289073396314
young j8.6289073396314
lindenfeld j8.6289073396314
consensus trial study group8.5920924788324
symptomatic nyha class ii8.5915760184806
ace inhibitor therapy8.5800543746011
systemic disease8.5291344178582
effect of carvedilol8.5242951907087
krishnaswamy p8.4852813742386
cardiovascular disease hospitalization8.4455351182242
low cardiac output8.4200214932682
third heart sound8.4078800764062
initial laboratory evaluation8.3925789638182
evaluation of patients8.3725700160278
casey de jr8.2985253256109
randomised trial8.1812469784701
cardiac-resynchronization therapy8.1739324901763
usual care8.1221727394757
adverse changes8.1072009288422
reduced mortality8.0770059874436
ischemic cardiomyopathy7.9921760297609
angiotensin-converting enzyme7.9774438454175
lee kl7.8964440777149
champion trial study group7.8789835426777
6-minute walk test7.845962916071
haarbo j7.7970979610547
neaton j7.7970979610547
pogue j7.7970979610547
emberson j7.7970979610547
bosch j7.7970979610547
mccord j7.7970979610547
gong j7.7970979610547
gallagher j7.7970979610547
mathew j7.7970979610547
care of patients7.7844093950776
randomized aldactone evaluation study investigators7.7057858141598
poor functional status7.5438910962342
angiotensin receptor?neprilysin inhibitors7.5417066766768
right ventricular function7.5395190889965
clinical guidelines7.5352689577953
implantable pulmonary artery pressure7.5053420380578
cardiomems heart sensor7.490569582348
left ventricular hypertrophy7.4659422745248
cardiac resynchronization therapy7.461797978668
acute pulmonary disease7.4527789849152
glycemic control7.4448388728168
randomized trial danish7.377854493525
american college of cardiology foundation/american heart association task force7.3615515350663
other risk factor7.3557314102613
20,985 patients7.3484692283495
swedberg k7.3484692283495
blood volume7.3256830029694
first hospitalization7.3256830029694
primary risk factors7.2867046089153
inhibitor ivabradine trial7.2716336769238
renal disease7.2560172494525
functional class guides treatment7.2225756445557
quality of care7.2217462736946
observational study7.1407419177511
zannad f7.1352426900163
subset of patients7.1352426900163
cardiovascular events7.1131176401557
medical history7.0851677179898
clinical studies7.0568830507494
disease progression6.9009799013736
advanced disease6.9009799013736
volume overload6.8795812565008
natriuretic peptide levels6.7807496594118
loop diuretics6.700737917669
clinical status6.673987930963
effects of treatment6.6706214794855
ventricular size6.6604914252356
danish study6.6452091262532
implantable cardioverter-defibrillator6.6400915182019
angiotensin-receptor blockers6.6400915182019
kazanegra r6.6195018392937
prophylactic implantation6.6195018392937
boineau r6.6195018392937
latini r6.6195018392937
outcomes of patients6.5934915059146
range of risk factor levels6.558071028175
american college of cardiology6.5412422314049
effects of candesartan6.4474195909412
usual clinical care6.3802363071573
major risk factors6.3655227986524
miracle icd trial6.3547610473256
history of hospitalization6.3442275806434
adverse effects6.3442275806434
cannom ds6.3442275806434
cardiac insufficiency bisoprolol study ii6.3179627563086
multicenter insync icd randomized clinical evaluation6.3095633402878
relative risk6.3086842910598
lifetime risk6.3086842910598
risk score6.3086842910598
atherosclerosis risk6.3086842910598
influence risk6.3086842910598
accf/aha guideline6.2926925672916
functional capacity of patients6.2273448933373
left-ventricular ejection fraction6.2133136519014
accf/aha guidelines6.1771812387753
subjective symptoms6.160140576482
serum digoxin levels6.1273116840957
klein h6.1256286272176
renal insufficiency6.1256286272176
effect of digoxin6.1015588940837
modification of risk factors6.0675163483893
other patients6.0615465140299
ventricular dyssynchrony6.0184333968691
ventricular arrhythmias6.0184333968691
ventricular enlargement6.0184333968691
stevenson lw6
shortness of breath6
such cardiovascular risk factors5.9621371715169
valvular disease5.957892135529
solvd investigators5.9436557324017
val-heft investigators5.9436557324017
charm investigators5.9436557324017
term gheart failure h5.9368741417647
clinical syndrome5.9341076602399
dietary sodium restriction5.9191344907092
controlled clinical trials5.8878964084292
cardiogenic shock5.8856619127654
other mechanisms5.8856619127654
previous myocardial infarction5.8653533983426
other adverse effects5.8601559088987
elevated systemic blood pressure5.8538734383683
significant differences5.8259012604879
oral diuretic therapy5.8249031191339
monitoring of pressure5.8106700157786
myocardial remodeling5.7991674783197
myocardial structure5.7991674783197
cardiovascular outcomes5.7850152170382
j card fail5.7714994741381
exercise capacity5.7326567532262
symptomatic management5.7326567532262
champion trial investigators5.717797486992
harrison a5.7005397655436
krum h5.7005397655436
rawshani a5.7005397655436
recognized risk factors5.6710361016125
nonmodifiable risk factors5.6710361016125
intensive blood pressure5.6586941766333
low doses5.5663153674275
packer m5.5663153674275
rates of hyperkalemia5.5663153674275
jessup m5.5663153674275
important adverse effects5.547933582892
daily pulmonary artery pressure readings5.5321413028549
cardiac toxicity5.5193380421438
cardiac output5.5193380421438
nonfatal myocardial infarction5.4820834359262
rates of hospitalization5.4772255750517
charm-preserved trial5.4711295994695
charm-alternative trial5.4711295994695
cardiac pump function5.442323265122
non-ischemic cardiomyopathy treatment evaluation5.438910834863
symptoms of volume overload5.4146047111091
advanced therapy5.3787500669746
large population study5.3481384667782
masson s5.3446902355676
barlera s5.3446902355676
madit-crt trial investigators5.3441695264733
prospective randomized cumulative survival study group5.3249941204811
gerdes am5.3049500053196
kucharska-newton am5.3049500053196
significant effect5.3049500053196
emphasis-hf study group5.2974318574102
held p5.26429605181
jourdain p5.26429605181
magnetic resonance imaging5.2414827884178
myocardial sarcomere5.2401393526787
clinical characteristics5.2226777991727
clinical benefit5.2226777991727
clinical assessment5.2226777991727
ventricular noncompaction cardiomyopathy results5.200849059796
optimal medical therapy5.1893987221281
mild symptoms5.1800401282227
functional status5.1800401282227
blood tests5.1800401282227
weight monitoring5.1800401282227
hypomagnesemia increase risk5.1660198496359
sudden death5.1510191538028
cardiac muscle5.1363228010461
cardiac structure5.1363228010461
digoxin dose5.0914597900437
ventricular dysfunction delays onset5.0761464007087
left-ventricular systolic function5.0719730249202
multinational study investigators5.0657970191009
multicenter automatic defibrillator implantation trial ii investigators5.0514818398486
elderly study5.0492670327448
effects of enalapril5.0453784915223
maladaptive ventricular hypertrophy5.0063266198115
enalapril group4.9737947036147
high risk of re-admission4.9241689779833
patient's clinical status4.9027522910779
randomised trial of losartan4.8760319739572
quality measures4.8645985581956
fluid restriction4.8645985581956
therapy changes4.8602493374348
drug therapy4.8602493374348
randomised placebo-controlled study4.8490562872798
increase exercise capacity4.8465663976689
ace inhibitor ramipril4.8409406455445
practice guidelines4.8339055525626
diabetes care4.8294728055328
independent risk factor4.8284476525076
absence of symptoms4.8205705136679
loop diuretic4.8205705136679
refractory symptoms4.8205705136679
pressure overload4.8026164940938
other factors4.7867398586908
sprint research study group4.7637250806784
disease process4.7381372205376
reduced diastolic4.7381372205376
lung disease4.7381372205376
clinical suggestions4.7192221235411
clinical suspicion4.7192221235411
african american patients4.7170518987602
large double-blind trial4.6980201586465
tognoni g4.6806946386414
ischemic stroke4.6806946386414
pulmonary causes of exercise limitation4.6806946386414
sudden cardiac death4.6575419678526
cardiac sarcoidosis4.6411915742122
cardiac involvement4.6411915742122
cardiac workload4.6411915742122
cardiac valves4.6411915742122
cardiac amyloidosis4.6411915742122
cause of death4.6361821858297
stars-bnp multicenter study4.6220442888931
mild patients hospitalization4.6196709652247
chronic atrial fibrillation4.6132323629156
association of serum digoxin concentration4.5916055846449
patient's nyha4.5825756949558
k?ber l4.5590141139096
effects of valsartan4.5590141139096
combination of ace inhibitors4.5582562960338
coronary angiography4.4860463436637
metoprolol cr/xl randomised intervention trial4.4287921839498
diabetes mellitus4.4267276788013
inefficient ventricular contractile function4.4248034309981
family history of cardiomyopathy4.4088173933227
initial evaluation4.3679267425564
prospective clinical trials4.3678557314809
bnp levels4.3558771746929
severity of symptoms4.3558771746929
oral diuretic dose4.3440506352097
other measures4.3253077270721
american college of physicians4.3231140296575
left-ventricular dysfunction4.2813902858562
conduction abnormalities4.2813902858562
givertz mm4.2813902858562
maladaptive ventricular remodeling4.2513258303959
prophylactic icd implantation4.2484406376281
other important guidelines4.2448203141176
right ventricular free wall4.2425598510497
composite outcome4.2294850537623
daubert jp4.2294850537623
plasma digoxin levels4.2227675591121
peripartum cardiomyopathy4.1824461364775
other systemic disorders4.1689486953466
cooperative north scandinavian enalapril survival study4.1683924274728
oral furosemide therapy4.1633714773242
recent observational study4.1623049031538
prophylactic icd4.1408245796559
objective measures of disease status4.1301657152851
sinus rate4.1195342878142
oxygen-rich blood4.1195342878142
blood flow4.1195342878142
blood counts4.1195342878142
reduced rates4.090623489235
à-blocker therapy4.0869662450882
first-line therapy4.0869662450882
appropriate therapy4.0869662450882
evaluation of losartan4.0648138508249
other important disorders4.0632051688874
routine care4.0610863697379
specific clinical indication4.0577694145156
exercise training4.0536004644211
role of palliative care4.0300296715324
maisel as4
gbridge therapy h3.9993486932656
pressure-guided management of patients3.9654064565002
serum levels of electrolytes3.9468319327726
moss aj3.9359793425309
staging system3.9359793425309
ezekowitz ja3.9359793425309
defibrillator implantation3.9359793425309
fluid retention3.9359793425309
patient information3.9359793425309
controlled studies3.9359793425309
gventricular dysfunction h3.9320768183025
effect of diuretics3.8985489805273
left bundle branch block3.8735854825302
adverse events3.8729833462074
pulmonary capillary wedge pressure3.8536671042695
arni treatment3.8512851068431
goal of treatment3.8512851068431
early treatment3.8512851068431
potential adverse effects3.8467222990467
intolerable adverse effects3.8467222990467
continuous intravenous inotropic agents3.8375885893579
carvedilol post-infarct survival control3.8375885893579
lo studio della streptochinasi nell finfarto miocardico-heart failure trial3.8349221943338
laboratory evidence3.8067540958393
peripheral vascular disease3.8027429028336
houston-miller n3.7976578442319
kagiyama n3.7976578442319
freemantle n3.7976578442319
heterogeneous study populations3.7817049765835
ivabradine group3.7792667089114
basic palliative care3.7666884513457
palliative care addresses3.7666884513457
aha stage c3.7578442412245
specific type of cardiomyopathy3.7439265731403
other treatment decisions3.7430197238696
patient's daily weight3.7288210710016
hall wj3.7224194364084
qrs duration3.7224194364084
bauman jg3.7224194364084
muscular dystrophy3.7224194364084
abraham wt3.7224194364084
larson mg3.7224194364084
pfeffer ma3.7224194364084
incessant tachycardia3.7224194364084
yancy cw3.7224194364084
bourge rc3.7224194364084
intravenous loop diuretics3.719046769829
global mortality3.7126875376323
adequate doses of ace inhibitors3.7098517435797
population-based reykjavik study3.708192102729
only therapy3.6929908877475
ordinary physical activity3.6830484346607
invasive evaluation3.6729739399065
safety of exercise training3.6666352749723
advanced stages3.6628415014847
b-type natriuretic peptide assay3.6628415014847
supervised exercise3.6628415014847
a1c levels3.6628415014847
other noninvasive imaging3.6590516533172
effect of metoprolol cr/xl3.6529276674218
european society of cardiology3.6467519140054
direct myocardial toxin?it3.6231148419824
increased mortality3.6161715709604
regional dysfunction3.6002057436785
sodium restriction3.6002057436785
digoxin toxicity3.6002057436785
serum level3.6002057436785
controlled trials3.6002057436785
inhibitor ramipril3.5840246342157
angiotensin-converting-enzyme inhibitor3.5840246342157
variety of patients3.5676213450082
arrhythmogenic right ventricular dysplasia3.567553370247
elevated total cholesterol levels3.5620857880302
health care costs3.561271038656
cardiovascular system3.5565588200778
volume status3.5565588200778
clinical slide set3.5447880909253
ability of icd implantation3.5376050502214
danish investigators3.5341188430494
renal excretion of digoxin3.503082197055
other medications3.4996355115806
other à-blockers3.4996355115806
other lifestyle changes3.4877505632064
miracle icd3.4820045452271
appropriate serum level of digoxin3.473041544387
hemodynamically significant ventricular septal defects3.4683547086532
felker gm3.4641016151377
cigarette smoking3.4641016151377
benjamin ej3.4641016151377
granger cb3.4641016151377
brown mw3.4641016151377
family history3.4641016151377
end-organ hypoperfusion3.4641016151377
davis ce3.4641016151377
few days3.4641016151377
stable weight3.4641016151377
united states3.4641016151377
hiv infection3.4641016151377
d fagostino r jr3.4519247197843
first-line drug therapy3.4458199066465
nondiabetic control group3.4312578792284
other relevant pqrs quality measures3.4278736200193
spironolactone group3.4149529703483
collaborative care3.4149529703483
guided care3.4149529703483
decrease hospitalization3.4086580994025
bundle branch block3.3967626591299
effect of spironolactone3.3895612242702
trabeculated myocardial architecture3.3863633634254
aha stage3.3635856610149
use of bnp3.3635856610149
prophylactic defibrillator implantation3.3604214537127
other performance measures3.3446807651574
other tests3.3437015248821
meta-analysis global group3.3285607270274
cardiopulmonary exercise test3.3244690547396
smith r3.3097509196469
natriuretic peptides3.3097509196469
genetic disorders3.3097509196469
careful monitoring of serum potassium levels3.2957569692557
severe cardiogenic shock3.2598444275496
current measures3.2531531233956
time-to-furosemide treatment3.2385318404644
hospital admission rate3.2377408137211
angiotensin-converting enzyme inhibitors3.2368032890054
atrial arrhythmia3.2237097954706
hospitalized patients3.2237097954706
selected patients3.2237097954706
natural history3.2237097954706
elevated levels of low-density lipoprotein cholesterol3.2113286293254
low high-density lipoprotein cholesterol levels3.2113286293254
detrimental effect of sodium restriction3.2033666669598
functional mitral regurgitation3.2031009475288
cardiopulmonary exercise testing3.2031009475288
obesity-related cardiomyopathy3.1779718278113
dilated cardiomyopathy3.1779718278113
tachycardia-induced cardiomyopathy3.1779718278113
diabetic cardiomyopathy3.1779718278113
eplerenone group3.1779718278113
hypertrophic cardiomyopathy3.1779718278113
ordinary physical activity results3.1616447614742
prediction of survival3.1463462836458
expected survival3.1463462836458
survival advantage3.1463462836458
meaningful survival3.1463462836458
noninvasive imaging3.1301691601466
long-term use3.1301691601466
aborted cardiac arrest3.1231391134797
smith al3.1054227990715
structured cardiac rehabilitation program3.0918884056739
high doses3.080070288241
large multicenter3.080070288241
nt-probnp levels3.080070288241
thiazide diuretic3.080070288241
electrolyte levels3.080070288241
current aha guidelines3.0668124740328
yancy c3.0628143136088
other genetic disorders of iron metabolism3.0600833060707
different types of care3.0569032462135
elevated jugular venous pressure3.0400841363597
systemic disorder3.0274001040351
practice improvement3.0274001040351
systemic diseases3.0274001040351
iron overload3.0274001040351
daily weight checks3.0261714988458
iervasi g. thyroid replacement therapy3.0061164174793
natriuretic peptide-based screening2.9937951655239
observational studies2.9906975624424
doukky r2.9906975624424
segal r2.9906975624424
quigg r2.9906975624424
comenzo r2.9906975624424
quality indicators2.9906975624424
marchioli r2.9906975624424
davies r2.9906975624424
lieberman r2.9906975624424
cody r2.9906975624424
deo r2.9906975624424
cremo r2.9906975624424
amirnovin r2.9906975624424
physical activities2.9718278662008
physical exam2.9718278662008
physical therapists2.9718278662008
predictors of mortality2.9525917237372
laboratory tests2.9428309563827
such reversible cardiac conditions2.9390867394432
hospital readmission rates2.9355985352441
long-term inotropic infusion2.9279034960725
specific structural abnormalities2.9279034960725
physician quality reporting system2.9278526754426
riegel b2.9129506302439
history of angioedema2.9129506302439
end-of-life management2.9129506302439
olofsson b2.9129506302439
increased bnp2.9129506302439
levin b2.9129506302439
eliasson b2.9129506302439
symptom management2.9129506302439
roniker b2.9129506302439
significant data2.9129506302439
wilkoff b2.9129506302439
claggett b2.9129506302439
diastolic relaxation2.9129506302439
reduced hospitalizations2.8925076085191
unexplained weight gain2.8844991406148
angiotensin-receptor blocker valsartan2.8844991406148
intensive hypertension control2.8844991406148
lot of weight gain2.8844991406148
angiotensin-converting-enzyme inhibitors2.882121417102
acute exacerbations2.8716217110259
placebo group2.8716217110259
sacubitril?valsartan group2.8716217110259
epicardial coronary arteries2.8536385282275
thyroid-stimulating hormone levels2.8536385282275
maggioni a2.8502698827718
left ventricle2.8502698827718
outpatient dose2.8284271247462
routine use2.8284271247462
ordinary activity2.8284271247462
selective aldosterone blocker2.8210130123402
combination of isosorbide dinitrate2.8077989890847
taylor al2.8060662632967
symptomatic bradycardia2.7831576837137
diuretic effectiveness2.7831576837137
lee ds2.7831576837137
diuretic strategies2.7831576837137
diuretic adjustments2.7831576837137
à-blockers carvedilol2.7831576837137
biomarker intensified treatment2.7578805125536
overall mortality2.7476962050545
structured aerobic exercise program2.746743631666
liver function2.7355647997348
rosengren a. glycaemic control2.7285232036427
levy d2.7108060108295
atrial abnormality2.7108060108295
important characteristics2.7108060108295
important organs2.7108060108295
long-term safety2.7108060108295
wide range of causes2.6960123091946
nonvalvular atrial fibrillation2.6889452937027
shift investigators2.6853496142827
topcat investigators2.6853496142827
paradigm-hf investigators2.6853496142827
warcef investigators2.6853496142827
gissi-hf investigators2.6853496142827
hf-action investigators2.6853496142827
hope investigators2.6853496142827
acute dyspnea2.6723451177838
formal exercise programs2.66716827534
other shunts2.6591479484725
le helloco a2.6571971456127
elkayam u. peripartum cardiomyopathy2.6521704180372
v-heft va cooperative studies group2.6379831394264
tolerated dose2.632148025905
significant reductions2.632148025905
last dose2.632148025905
sodium intake2.632148025905
significant reduction2.632148025905
angiotensin-receptor blocker2.632148025905
elevated bnp2.632148025905
current medications2.632148025905
ann intern med2.6207413942089
selective aldosterone antagonist2.6084654714896
several consensus guidelines2.6043085235871
heterogeneous group of outpatients2.5958936998277
hemodynamic monitoring2.5900200641113
cushman m2.5900200641113
baggett c2.5755095769014
avezum a2.5755095769014
perez a2.5755095769014
rapezzi c2.5755095769014
chavelas c2.5755095769014
kiran a2.5755095769014
dan a2.5755095769014
barth c2.5755095769014
dyer a2.5755095769014
yilmaz a2.5755095769014
shi h2.5755095769014
castaigne a2.5755095769014
mangla a2.5755095769014
henrick a2.5755095769014
dubost-brama a2.5755095769014
laupacis a2.5755095769014
kopp a2.5755095769014
ukena c2.5755095769014
avogaro a2.5755095769014
conlon c2.5755095769014
kadish a2.5755095769014
glomerular filtration rate2.5697965868507
tolerated dose of à-blockers2.5697965868507
intravenous bolus2.5457298950218
definitive evidence2.5457298950218
strong evidence2.5457298950218
aldosterone antagonists2.5457298950218
causative factors2.5457298950218
digitalis investigation group2.5454319088428
short-term symptomatic benefits2.5423029068338
used loop diuretics2.5132368765511
parasuraman s. glycemic control2.5020668097181
in-hospital mortality2.4828237961984
physician quality reporting initiative?that clinicians2.4754341287137
overt cardiogenic shock2.4662120743305
rapid b-natriuretic peptide assay2.4494897427832
advanced therapies2.4494897427832
primary outcome2.4494897427832
kavalieratos d2.4494897427832
logeart d2.4494897427832
same population2.4494897427832
lifestyle modifications2.4494897427832
aguilar d2.4494897427832
johnstone d2.4494897427832
ettehad d2.4494897427832
mozaffarian d2.4494897427832
gras d2.4494897427832
valvular abnormalities2.4322992790978
joshua-gotlib s2.4147364027664
franz?n s2.4147364027664
kuroda s2.4147364027664
homma s2.4147364027664
ziesche s2.4147364027664
gudbj?rnsdottir s2.4147364027664
non?left bundle branch block pattern2.3924623977026
carson p2.3784142300054
clopton p2.3784142300054
severe comorbidities2.3784142300054
maximum dose2.3784142300054
beyne p2.3784142300054
severe signs2.3784142300054
sleight p2.3784142300054
gueffet p2.3784142300054
use age2.3784142300054
elliott p2.3784142300054
mohacsi p2.3784142300054
afterload-reducing agents2.3784142300054
duc p2.3784142300054
dennison himmelfarb c2.3672935308725
terms gcardiomyopathy h2.3672935308725
dei cas a2.3672935308725
systemic lupus erythematosus2.3490100793233
continuous intravenous administration2.3490100793233
multicenter guide-it2.3403473193207
komajda m2.3403473193207
lenski m2.3403473193207
miftaraj m2.3403473193207
diagnostic tests2.3403473193207
lind m2.3403473193207
b?hm m2.3403473193207
fiuzat m2.3403473193207
olsson m2.3403473193207
à-blocker carvedilol2.3403473193207
ledwidge m2.3403473193207
semigran m2.3403473193207
electrocardiographic monitoring2.3403473193207
hospital-level 30-day mortality2.3101522238684
robust predictor of mortality2.3101522238684
oral anticoagulants2.3003266337912
nma/pcna guideline2.3003266337912
oral torsemide2.3003266337912
patient's outpatient2.3003266337912
guiding evidence2.3003266337912
conflicting evidence2.3003266337912
optimal therapeutic range2.2894284851067
replacement device2.2795070569548
maisel a. utility2.2449240966188
hood wb jr2.2390395117024
several medications2.2133638394006
subjective assessment2.2133638394006
modification of hypertension2.2133638394006
martinez f2.2133638394006
healthcare research2.2133638394006
2-lb increase2.2133638394006
avery e2.2133638394006
5-lb increase2.2133638394006
diverse range2.2133638394006
impact of diabetes2.2133638394006
general population2.2133638394006
patient's subjective experience2.1955146386099
stroke statistics subcommittee2.1822472719434
role of lifestyle modifications2.1822472719434
deswal a. relationship of hemoglobin2.1810154653305
nonsudden death2.165736770668
hemodynamic overload2.1406951429281
thiazide diuretics2.1406951429281
tobacco use screening2.1398263878673
many genetic cardiomyopathies2.1398263878673
alternative imaging methods2.1398263878673
ojamaa k. thyroid hormone2.1351847961967
serious health condition2.1169328630255
thorgeirsson g2.1147425268811
thabut g2.1147425268811
meurers g2.1147425268811
johnson g2.1147425268811
dagenais g2.1147425268811
jondeau g2.1147425268811
ginn g2.1147425268811
noninvasive computed tomographic angiography2.1039790110173
author thanks lee r. goldberg2.0827594879848
effective gsliding h regimen2.0812192439376
djousse l2.0597671439071
hood wb2.0597671439071
tavazzi l2.0597671439071
long-term benefit2.0597671439071
damman k2.0597671439071
rapid measurement2.0597671439071
matsushita k2.0597671439071
primary prophylaxis2.0597671439071
lenert l2.0597671439071
ramasubbu k2.0597671439071
malmberg k2.0597671439071
additional medications2.0597671439071
kappenberger l2.0597671439071
angelici l2.0597671439071
ferdinand k2.0597671439071
fibrofatty replacement2.0597671439071
videb?k l2.0597671439071
2-dimensional doppler echocardiography2.0396489026555
two-dimensional doppler echocardiography2.0396489026555
additional diagnostic testing2.0396489026555
prognostic value of changes2.0396489026555
raimondi e2
korup e2
chemotherapeutic agents trastuzumab2
total distance2
tallon e2
funck f2
suspected cases2
long-standing untreated hypertension2
daubert jc2
mahfoud f2
million persons2
7.5 mg2
beauvais f2
donal e2
million hospital discharges2
hemoglobin a1c2
erdmann e2
o fconnell e2
prospective comparison of arni2
home health staff1.9786024464679
lindenfeld ja1.9679896712654
prognostic information1.9679896712654
high-risk populations1.9679896712654
combination of hydralazine1.9679896712654
downloadable guideline algorithm1.9559811771959
wall-motion abnormalities1.9343364202677
thune jj1.9343364202677
active ischemia1.9343364202677
mamdani mm1.9343364202677
redfield mm1.9343364202677
patient's circumstances1.9343364202677
teerlink jr1.9343364202677
scheinman mm1.9343364202677
glucose abnormalities1.9343364202677
colvin mm1.9343364202677
excess iron deposition1.9063685859939
long-acting metoprolol succinate1.9063685859939
implantable cardioversion defibrillation1.9063685859939
sustained efficacy1.8612097182042
goldberg lr1.8612097182042
alcohol consumption1.8612097182042
vago t1.8612097182042
efficacy of icds1.8612097182042
many areas1.8612097182042
absence of arrhythmia1.8612097182042
remme wj1.8612097182042
continuous infusion1.8612097182042
social support1.8612097182042
direct toxicity1.8612097182042
new agent1.8612097182042
first calls1.8612097182042
hardarson t1.8612097182042
routine anticoagulation1.8612097182042
definitive therapies1.8612097182042
major hemorrhage1.8612097182042
aspelund t1.8612097182042
yamaguchi t1.8612097182042
objective predictors1.8612097182042
callender t1.8612097182042
common precursor molecule1.8493111942973
composite end point1.8493111942973
regular measurement of electrolytes1.8171205928321
improved safety profiles1.8171205928321
van veldhuisen dj1.7817974362807
early postpartum period1.7817974362807
complete follow-up results1.7817974362807
several regulatory agencies1.7817974362807
review of animal models1.7817974362807
composite of time1.7782794100389
common questions1.7782794100389
preventable syndrome1.7782794100389
frequent hospitalizations1.7782794100389
combination of sacubitril1.7782794100389
heart-failure events1.7782794100389
recurrent hospitalizations1.7782794100389
neyra ja1.7782794100389
curtis jp1.7782794100389
biventricular pacing1.7782794100389
boehmer jp1.7782794100389
coats aj1.7782794100389
cowley aj1.7782794100389
peripheral edema1.7320508075689
same benefits1.7320508075689
strong muscle1.7320508075689
collins kj1.7320508075689
cushman wc1.7320508075689
aortic regurgitation1.7320508075689
maggioni ap1.7320508075689
levy wc1.7320508075689
remme w1.7320508075689
wang y1.7320508075689
stable outpatients1.7320508075689
peak oxygen consumption1.6983813295649
paroxysmal nocturnal dyspnea1.6983813295649
last trimester of pregnancy1.6983813295649
giant cell myocarditis1.6983813295649
shantsila e. anticoagulation1.6983813295649
katus ha1.6817928305074
franzosi mg1.6817928305074
whellan dj1.6817928305074
evans jc1.6817928305074
sound waves1.6817928305074
freudenberger rs1.6817928305074
one meta-analysis1.6817928305074
stress testing1.6817928305074
increases regression1.6817928305074
wilber dj1.6817928305074
muscular dystrophies1.6817928305074
white persons1.6817928305074
episodic arrhythmia1.6817928305074
ellis sj1.6817928305074
desai as1.6817928305074
packer dl1.6817928305074
qrs prolongation1.6817928305074
nielsen jc1.6817928305074
tycon le1.6817928305074
systematic review1.6817928305074
rare disorder1.6817928305074
klein hu1.6817928305074
major problem1.6817928305074
beanlands rs1.6817928305074
unpredictable exacerbations1.6817928305074
elimination of tachycardia1.6817928305074
slight limitation1.6817928305074
poor prognosis1.6817928305074
many parts1.6817928305074
black persons1.6817928305074
rheumatologic diseases1.6817928305074
ha ac1.6817928305074
cleland jg1.6817928305074
marked limitation1.6817928305074
wall thickness1.6817928305074
serial echocardiography1.6817928305074
enrollment goal1.6817928305074
drink alcohol1.6817928305074
heritable disorder1.6817928305074
vasan rs1.6817928305074
african americans1.6817928305074
ambrosius wt1.6817928305074
cochrane database syst rev1.6817928305074
wood ma1.6817928305074
dietary recommendations1.6817928305074
million people1.6817928305074
keteyian sj1.6817928305074
select therapies1.6817928305074
ellison rc1.6817928305074
inflammatory diseases1.6817928305074
suitable alternative1.6817928305074
pocock sj1.6817928305074
insoluble fibrillar proteins1.5874010519682
myocyte adipose accumulation1.5874010519682
autosomal dominant mutations1.5874010519682
complex psychosocial issues1.5874010519682
emdin ca1.5650845800733
fitzpatrick ap1.5650845800733
low-sodium diet1.5650845800733
n-terminal pro?b1.5650845800733
lower-extremity edema1.5650845800733
n-terminal pro-brain1.5650845800733
das sr1.5650845800733
rathore ss1.5650845800733
bristow mr1.5650845800733
anstrom kj1.5650845800733
former condition1.5650845800733
avery cl1.5650845800733
collins sp1.5650845800733
decrease afterload1.5650845800733
jensen dn1.5650845800733
audrey wu1.5650845800733
hollander je1.5650845800733
costanzo mr1.5650845800733
nery pb1.5650845800733
khan ss1.5650845800733
gudnason v1.5650845800733
ariti ca1.5650845800733
dr. wu1.5650845800733
shinbane js1.5650845800733
loehr lr1.5650845800733
wang tj1.5650845800733
second calls1.5650845800733
professional roles1.5650845800733
nowak rm1.5650845800733
matsue y1.5650845800733
emergency department1.5650845800733
developed areas1.5650845800733
anderson kp1.5650845800733
rizkala ar1.5650845800733
juurlink dn1.5650845800733
ann arbor1.5650845800733
nonpharmacologic interventions1.5650845800733
specialized interventions1.5650845800733
cavity size1.5650845800733
leon ar1.5650845800733
short-term basis1.5650845800733
borer js1.5650845800733
carey rm1.5650845800733
previous version1.5650845800733
enough data1.5650845800733
goldsmith sr1.5650845800733
hereditary hemochromatosis1.5650845800733
intracerebral hemorrhage1.5650845800733
overall frailty1.5650845800733
variety of antigens1.5650845800733
intracardiac device1.5650845800733
impact of obesity1.5650845800733
wilson pw1.5650845800733
nutritional supplements1.5650845800733
hypersensitivity myocarditis1.5650845800733
poole je1.5650845800733
hereditary anemias1.5650845800733
bekelman db1.5650845800733
aortic stenosis1.5650845800733
zareba w1.5650845800733
ibrahim z1.5650845800733
young jb1.5650845800733
mark db1.5650845800733
compared hydralazine1.5650845800733
plasma brain1.5650845800733
low-salt diet1.5650845800733
anderson sg1.5650845800733
various organs1.5650845800733
nutritional deficiencies1.5650845800733
arany z1.5650845800733
martinez fa1.5650845800733
professional organizations1.5650845800733
adamson pb1.5650845800733
kutyifa v1.5650845800733
allergic reaction1.4142135623731
michelson el1.4142135623731
bonow ro1.4142135623731
vision disturbances1.4142135623731
leip ep1.4142135623731
gottlieb so1.4142135623731
cropp ab1.4142135623731
cool extremities1.4142135623731
sinoatrial node1.4142135623731
walsh cr1.4142135623731
painful gynecomastia1.4142135623731
krumholz hm1.4142135623731
arnold jm1.4142135623731
urgent-care setting1.4142135623731
unrealistic expectations1.4142135623731
medicaid services1.4142135623731
fowler mb1.4142135623731
angiotensin-neprilysin inhibition1.4142135623731
mayo clinic1.4142135623731
congenital lesions1.4142135623731
aronow ws1.4142135623731
bates jt1.4142135623731
painless procedure1.4142135623731
past decade1.4142135623731
estes na1.4142135623731
collado fm1.4142135623731
zhang zm1.4142135623731
expert opinion1.4142135623731
chiuve se1.4142135623731
heavy toll1.4142135623731
hazard ratio1.4142135623731
thompson jl1.4142135623731
effort intolerance1.4142135623731
influenza immunization1.4142135623731
thiamine deficiency1.4142135623731
predetermined threshold1.4142135623731
predicted distances1.4142135623731
industrialized countries1.4142135623731
university of michigan1.4142135623731
assmann sf1.4142135623731
ellenbogen ka1.4142135623731
smoke cigarettes1.4142135623731
progressive weakness1.4142135623731
gelfman lp1.4142135623731
linker dt1.4142135623731
bonus payments1.4142135623731
pullicino pm1.4142135623731
bardy gh1.4142135623731
maurer ms1.4142135623731
lefkowitz mp1.4142135623731
endomyocardial biopsy1.4142135623731
gruppo italiano1.4142135623731
noncaseating granulomata1.4142135623731
ikejiani dz1.4142135623731
place chairs1.4142135623731
sex-specific equations1.4142135623731
repeated transfusions1.4142135623731
viable myocardium1.4142135623731
reasonable expectation1.4142135623731
soliman ez1.4142135623731
loeb hs1.4142135623731
daniels lb1.4142135623731
swollen feet1.4142135623731
radionuclide ventriculography1.4142135623731
fconnor cm1.4142135623731
bull da1.4142135623731
euthyroid state1.4142135623731
albert nm1.4142135623731
speed of absorption1.4142135623731
poulin mf1.4142135623731
attractive possibility1.4142135623731
sutradhar sc1.4142135623731
characteristic presentation1.4142135623731
shown promise1.4142135623731
drazner mh1.4142135623731
straight line1.4142135623731
blaha mj1.4142135623731
mentz rj1.4142135623731
cleavage products1.4142135623731
journal circulation1.4142135623731
voors aa1.4142135623731
adams kf1.4142135623731
cooper ls1.4142135623731
extent of disability1.4142135623731
abdominal bloating1.4142135623731
chang pp1.4142135623731
austin pc1.4142135623731
healthy adults1.4142135623731
tool kit1.4142135623731
dao q1.4142135623731
squire ib1.4142135623731
prior chemotherapy1.4142135623731
whelton pk1.4142135623731
nichols ga1.4142135623731
dargie hj1.4142135623731
birnie dh1.4142135623731
future priorities1.4142135623731
morrison lk1.4142135623731
educational material1.4142135623731
self-care guide1.4142135623731
lip gy1.4142135623731
striated muscles1.4142135623731
anorexia nervosa1.4142135623731
executive summary1.4142135623731
obvious explanation1.4142135623731
anker sd1.4142135623731
neurohormonal activation1.4142135623731
j.jacc .2016.03.6051
.0 b013e31829e88071
1.2 ng/ml1
0.8 ng/ml1
2.5 times1

頻出語ITC103

抽出語出現回数 抽出語出現回数 抽出語出現回数
failure236clinician16obesity9
heart217function16activity8
patient145infarction16advanced8
risk53american15adverse8
disease49arb15atrial8
ventricular42blood15current8
mortality41cardiovascular15drug8
-rsb-_NN39hypertension15evaluation8
therapy39severe15higher8
inhibitor35they15hydralazine8
not35à-blocker14important8
you34weight14mild8
symptom33chronic13morbidity8
trial33circulation13more8
ejection30diabetes13placebo8
fraction30digoxin13primary8
myocardial28management13pulmonary8
investigator27significant13addition7
it27survival13all-cause7
other27diuretic12asymptomatic7
who27dose12benefit7
clinical26exercise12change7
coronary26more12congestive7
dysfunction26physical12controlled7
cardiac25which12day7
factor25diastolic11disorder7
hospitalization25functional11enalapril7
artery24history11even7
effect23natriuretic11f7
that23test11greater7
also22condition10however7
systolic22control10hypertrophy7
guideline21diagnosis10information7
less21implantation10j.jacc7
level21large10many7
pressure21peptide10population7
class20renal10prevention7
such20significantly10quality7
what20specific10reduction7
cardiomyopathy19standard10result7
study19symptomatic10sign7
treatment19abnormality9sinus7
I18agent9smoking7
rate18decompensated9status7
death17evidence9support7
outcome17group9systemic7
when17high9volume7
acute16left9ace6
care16lower9blocker6
cause16medical9combination6